<DOC>
	<DOC>NCT00831441</DOC>
	<brief_summary>The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome</brief_summary>
	<brief_title>Phase III Acute Coronary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>Acute coronary syndrome (ACS) Clinically stable Receiving standard of care for ACS Severe hypertension Active bleeding or high risk for major bleeding Hemoglobin &lt; 9 g/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>NOS</keyword>
</DOC>